Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats

British Journal of Pharmacology
Sheila M GardinerTerence Bennett

Abstract

The regional haemodynamic effects of rat or human urotensin II (U-II) 3, 30, 300 and 3000 pmol kg(-1), i.v.) were assessed in separate groups of conscious, unrestrained, male, Sprague-Dawley rats (n=8 in each). Rat and human U-II had similar effects. At a dose of 3 pmol kg(-1), neither peptide had any significant action, while at a dose of 30 pmol kg(-1), there was a transient mesenteric vasodilatation (significant only for rat U-II). At doses of 300 and 3000 pmol kg(-1), there were dose-dependent tachycardias, and mesenteric and hindquarters hyperaemic vasodilatations. Thus, in conscious rats, the predominant cardiovascular action of rat and human U-II is vasodilatation. This is in contrast to recent findings with human U-II in non-human primates, but is consistent with effects on human isolated resistance vessels.

References

Dec 1, 1986·General and Comparative Endocrinology·A GibsonH A Bern
May 1, 1987·British Journal of Pharmacology·A Gibson
Dec 23, 1998·Proceedings of the National Academy of Sciences of the United States of America·Y CoulouarnH Vaudry
Nov 5, 1999·Biochemical and Biophysical Research Communications·M MoriM Fujino
Dec 3, 1999·Biochemical and Biophysical Research Communications·Q LiuC T Caskey
Aug 22, 2000·British Journal of Pharmacology·F E BottrillR White
Oct 6, 2000·European Journal of Pharmacology·O Saetrum OpgaardD N Krause

❮ Previous
Next ❯

Citations

Nov 5, 2004·Naunyn-Schmiedeberg's Archives of Pharmacology·Raffaella VerguraDomenico Regoli
Aug 19, 2007·Naunyn-Schmiedeberg's Archives of Pharmacology·Ana Patrícia Fontes-SousaAdelino F Leite-Moreira
Aug 8, 2007·Journal of Anesthesia·John McDonaldDavid G Lambert
May 11, 2005·Cardiovascular Drugs and Therapy·Kwok Leung OngBernard M Y Cheung
Mar 17, 2007·Current Hypertension Reports·Henry Krum, Will Kemp
Apr 23, 2004·Trends in Pharmacological Sciences·Stephen A DouglasDouglas G Johns
Nov 26, 2002·Journal of Hepatology·Jörg HellerTilman Sauerbruch
Nov 5, 2002·Bioorganic & Medicinal Chemistry·Paolo GriecoPaolo Rovero
Apr 12, 2003·Current Opinion in Pharmacology·Terence Bennett, Sheila M Gardiner
Jan 12, 2002·British Journal of Pharmacology·Felix Böhm, John Pernow
Oct 17, 2002·British Journal of Pharmacology·Janet J Maguire, Anthony P Davenport
Mar 5, 2009·British Journal of Anaesthesia·A D LeonardD G Lambert
Apr 17, 2008·Cardiology in Review·Nirav DesaiWilliam H Frishman
Oct 1, 2010·Clinical and Experimental Pharmacology & Physiology·Nicoletta NitescuGregor Guron
Jan 24, 2007·Acta Pharmacologica Sinica·Yu-ming WuRui-rong He
Nov 19, 2003·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Yingzi LinMitsuo Iida
Jul 8, 2009·Digestive Diseases and Sciences·Ludger LeifeldUlrich Spengler
Mar 15, 2006·Kidney International·W SongN Ashton
Jul 9, 2008·Cardiovascular Revascularization Medicine : Including Molecular Interventions·Rajbabu Pakala
Jan 15, 2008·Experimental Neurology·Julien ChuquetOmar Touzani
Dec 25, 2007·Peptides·Christophe D ProulxRichard Leduc
Oct 16, 2007·Peptides·Markus Tölle, Markus van der Giet
Jul 6, 2007·Peptides·Kwok Leung OngBernard M Y Cheung
May 14, 2005·Annals of the New York Academy of Sciences·R J BalmentN Ashton
Sep 2, 2004·British Journal of Pharmacology·Sheila M GardinerTerence Bennett
Jun 20, 2006·British Journal of Pharmacology·Yi-Chun ZhuPhilip Keith Moore
Nov 30, 2005·British Journal of Pharmacology·Sheila M GardinerTerence Bennett
Jan 11, 2007·British Journal of Pharmacology·J-s QiB P Damiano
Oct 9, 2007·Liver International : Official Journal of the International Association for the Study of the Liver·William KempStuart Roberts
Mar 6, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jonel TrebickaJörg Heller
Jul 17, 2010·Annals of the New York Academy of Sciences·Hubert VaudryJérôme Leprince
Oct 13, 2004·Peptides·George ThanassoulisAdel Giaid
Oct 13, 2004·Peptides·Takanobu YoshimotoYukio Hirata
Oct 13, 2004·Peptides·Anna M D Watson, Clive N May
Oct 13, 2004·Peptides·A Mark Richards, Chris Charles
Oct 7, 2004·Pharmacology & Therapeutics·Fraser D Russell
Apr 28, 2004·Trends in Endocrinology and Metabolism : TEM·Döne OnanWalter G Thomas
Jun 5, 2014·Journal of Experimental & Clinical Cancer Research : CR·Renato FrancoMichele Caraglia

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.